Somewhat Critical Press Coverage Somewhat Unlikely to Affect Cellect Biotechnology Ltd. – American Depositary Shares (APOP) Stock Price

News articles about Cellect Biotechnology Ltd. – American Depositary Shares (NASDAQ:APOP) have trended somewhat negative this week, Accern reports. The research group identifies positive and negative news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cellect Biotechnology Ltd. – American Depositary Shares earned a daily sentiment score of -0.09 on Accern’s scale. Accern also gave press coverage about the company an impact score of 47.4433929841867 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

APOP has been the subject of several research reports. HC Wainwright set a $14.00 target price on shares of Cellect Biotechnology Ltd. – American Depositary Shares and gave the company a “buy” rating in a report on Friday, January 5th. ValuEngine downgraded shares of Cellect Biotechnology Ltd. – American Depositary Shares from a “hold” rating to a “sell” rating in a report on Friday, December 1st.

Cellect Biotechnology Ltd. – American Depositary Shares (NASDAQ APOP) traded up $0.09 during trading on Wednesday, reaching $7.57. 14,100 shares of the company traded hands, compared to its average volume of 206,500. Cellect Biotechnology Ltd. – American Depositary Shares has a 12-month low of $5.12 and a 12-month high of $13.50. The firm has a market cap of $42.36 and a P/E ratio of -11.30.

Cellect Biotechnology Ltd. – American Depositary Shares (NASDAQ:APOP) last posted its earnings results on Wednesday, November 22nd. The company reported ($0.39) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.09). analysts predict that Cellect Biotechnology Ltd. – American Depositary Shares will post -1.66 EPS for the current year.

WARNING: This article was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/14/somewhat-critical-press-coverage-somewhat-unlikely-to-affect-cellect-biotechnology-ltd-american-depositary-shares-apop-stock-price.html.

About Cellect Biotechnology Ltd. – American Depositary Shares

Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.

Insider Buying and Selling by Quarter for Cellect Biotechnology Ltd. - American Depositary Shares (NASDAQ:APOP)

Receive News & Ratings for Cellect Biotechnology Ltd. - American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellect Biotechnology Ltd. - American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply